Neurocrine Biosciences, Inc. (NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs TranscriptSeeking Alpha • 12/17/25
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and EndocrinologyPRNewsWire • 12/16/25
Leading Drug Stock Fights To Regain Buy Point At Key Resistance LevelInvestors Business Daily • 12/05/25
Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/02/25
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) CapsulesPRNewsWire • 11/20/25
A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences FurtherSeeking Alpha • 11/19/25
Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/18/25
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety ProfileBenzinga • 11/11/25
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive DisorderPRNewsWire • 11/10/25
Biotech is back. Here's why these rallying stocks belong in your portfolio now.Market Watch • 11/03/25
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 EarningsZacks Investment Research • 10/29/25
Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza QuarterInvestors Business Daily • 10/28/25
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great ChoiceZacks Investment Research • 10/24/25
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg CapsulesPRNewsWire • 10/17/25
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial ResultsPRNewsWire • 10/07/25